



Pfizer ApS  
Lautrupvang 8  
DK-2750 Ballerup  
Tlf.: 44 20 11 00  
Fax: 44 20 11 02  
www.pfizer.dk  
CVR.nr. 66351912

Pfizer Danmark

Dansk Selskab for Klinisk Onkologi (DSKO)  
Rigshospitalet, Finsencentret  
Blegdamsvej 9  
2100 København Ø  
Att.: Afd. Læge Nicolaj Andreassen

Ballerup, 3.2.2017

**Agreement on support to: DSKO's (Dansk Selskab for Klinisk Onkologi) Årsmøde 2017 den 23-25. marts 2017 på Hotel Nyborg Strand.**

**Parties**

Pfizer ApS (hereafter Pfizer) wishes to provide support to DSKO's Årsmøde 2017 and has therefore entered into this Agreement with DSKO.

**Scope and purpose of the Agreement**

The purpose of this agreement shall be to support the scientific part of the DSKO annual meeting 23<sup>rd</sup> to 25<sup>th</sup> March 2017 at Hotel Nyborg Strand with an amount of 29.000,00 DKK. 18.000 DKK will be the price for the booth and 11.000 DKK will be a sponsorship for the meeting.

The support Pfizer will provide is given under the condition that it is used to cover expenses in connection with academic and scientific activities including appropriate amount of food and beverages. It may not be used to sponsor or organize activities of a solely social or cultural character or any other non-academic activities.

**Roles of the parties in the project**

Pfizer undertakes during the terms of this Agreement to sponsor the annual meeting with 29.000,00 DKK.

In return Pfizer will be mentioned in the program for the meeting, Pfizer's company logo will be in the program for the meeting, there will be a booth 3x3 meters in the coffee break area for Pfizer to use and 1 Pfizer employee will get admittance to the scientific part of the annual meeting including lunch and coffee breaks.

Any promotional activity/display must be separated from all academic and scientific activities and in addition it must be separated from the general public.

Please be aware that according to ENLI rules no gifts must be provided to healthcare professionals, unless they fall into a category of items that are otherwise permitted under the ENLI code. This prohibition applies for all activities sponsored or co-sponsored by a pharmaceutical company.

**Timeframe**

The agreement shall run from 23. March 2017 to 25. March 2017.

**Financial support**

Pfizer's financial commitment in relation to this Agreement shall be 29.000,00 DKK excl. VAT.

**Report of activity to ENLI**

The sponsorship is reported to ENLI (The Ethical Committee for the Pharmaceutical Industry), prior to the activity and by Pfizer's opinion it is in compliance with all applicable rules although the arrangement has not been pre-approved by ENLI.

**Documentation**


Upon Pfizer's request, the Organization shall provide documentation that the support is spend in accordance with the Agreement and that the combined support does not exceed the actual expenses. Please be aware that DSKO, according to ENLI rules, will not be entitled to keep any surplus from the sponsorship and that funding not used for activities of a professional medical nature should be refunded.


**Data Privacy**

Information regarding name and contact information in relation to this agreement will be stored in a Pfizer global electronic system. You should be aware that some of the members of Pfizer group, legal counsel and/or regulatory authorities could have access to information as described above are located in countries whose laws protecting personal information may not be equivalent to those in your country. In particular, personal data disclosed to Pfizer Inc. by members of the Pfizer group within the European Economic Area and Switzerland are protected by Pfizer Inc.'s participation in the "safe harbour" schemes administered by the U.S. Department of Commerce.

You have right to access or, where incorrect, amend information pertaining to you that is in Pfizer's possession.

By signing this Agreement you confirm to have read and understood Pfizer's Representations and Warranties pursuant to Appendix A ("Representations and Warranties") and that the support is spend in accordance with the above mentioned terms and conditions.

Date: 3/2-2017  
Signature of authorized signatory on behalf of Pfizer ApS.  
  
Name: Lone Gamrath  
Title: Commercial Strategy Manager

Date: 24/2 17  
Signature of authorized signatory on behalf of DSKO.  
  
Name: Nicolaj Andreassen  
Title: MD and responsible for DSKO annual meeting

**Appendix A - Representations and Warranties**

- 1.1 The financial support from Pfizer will not cause your entity and, to your knowledge, any individuals affiliated with your entity or this support, to do anything that would result in Pfizer improperly obtaining or retaining business or gaining any improper business advantage;
- 1.2 Neither your entity nor, to your knowledge, any individuals affiliated with your entity or this support, will use any portion of the financial support from Pfizer to directly or indirectly offer or pay any money or anything of value in an effort to influence any Government Official or any other person in order for Pfizer to improperly obtain or retain business or to gain an improper business advantage, and, have not accepted, and will not accept in the future, such a payment;
- 1.3 If the support is an educational grant or otherwise to support an educational program, your entity agrees to disclose the fact that Pfizer is providing financial support for the educational program;
- 1.4 Pfizer may at any time publicly disclose that it has provided you with financial support, including the amount of such support; and
- 1.5 Pfizer will be entitled to revoke or suspend any financial support if Pfizer learns that your entity or any individuals affiliated with your entity or this support has used or intends to use any portion of the support to improperly seek to influence any Government Official or any other person in order to obtain or retain business or gain a business advantage.